Elderly IBD patients are at an increased risk for adverse events with therapy because of increased comorbidity, polypharmacy, and age-related physiologic changes. Antitumor necrosis factor (anti-TNF) therapy has been shown to improve remission rates and reduce rates of surgery and hospitalizations. 1 However, few studies have investigated the safety of anti-TNF therapy in elderly IBD patients.
Our experience from a community practice specialized in treating patients with inflammatory bowel disease was included. Fifty-four patients on anti-TNF were identified with 16 (29.6%) patients over 65 years old (9 men; 7 with ulcerative infection (UC) and 9 with Crohn's disease (CD); 5 treated with adalimumab, 8 with infliximab, and 3 with certolizumab). The control group consisted of 38 patients, 65 years old or younger (17 men; 11 UC and 27 CD; 14 treated with adalimumab, 15 with infliximab, and 9 with certolizumab).
The mean duration of anti-TNF therapy in the elderly was 44.3 months (standard deviation [SD] = 32.2), compared to 47.5 months (SD = 41.4) in controls (P = 0.79). The discontinuation rate of anti-TNF due to side effects was not significantly different between these two groups, with 9/38 (23.7%) in elderly versus 3/16 (18.8%) in controls (P = 1.00). Among elderly patients, 43.8% developed infections, with 12.5% of Clostridium difficile infection, 6.3% of abscess, and 25% of upper respiratory infection (URI). Among younger patients, 31.6% developed infections, with 7.9% of abscess, 2.6% of pneumonia, 18.4% of URI, and 2.6% of shingles. There was no significant difference in infection rate between these two groups (P = 0.39). However, the rate of hospitalization related to side effects of anti-TNF was significantly higher in the elderly (25%) (2 patients with C. difficile infection, 1 with abscess, and 1 with drug induced lupus), compared to younger patients (0) (P = 0.006). The elderly appeared to have higher risk for developing malignancy than younger patients (12.5% vs. 5.3%), although it was statistically nonsignificant (P = 0.57). All these patients who developed malignancies were on both anti-TNF and immunomodulators ( Table 1 ). The surgical intervention for chronic disease, fulminant disease, dysplasia or malignancy was not significantly different between the elderly and controls.
The safety and efficacy of the anti-TNF therapy in elderly IBD patients have not been well established, since most clinical trials and large observational cohorts primarily focus on younger patients. An Italian study 2 reported an increased rate of severe infections in elderly IBD patients with a 10% mortality compared to younger patients treated with biologics. Our study indicates that elderly IBD patients on anti-TNF therapy had more serious infections prompting hospitalizations but the overall infection rate was not different from younger patients. Combining therapy of anti-TNF and immunomodulators may also increase the risk of developing malignancy in the elderly. 
